We believe in delivering precision oncology to patients and physicians, empowering them with clear answers—and peace of mind—about their cancer treatment path.
Quicker, more comprehensive results lead to better planning. Order
#MammaPrint
and
#BluePrint
from your core biopsy to personalize your treatment every step of the way:
Our
#MammaPrint
and
#BluePrint
genomic tests add increased certainty to treatment decisions for early-stage
#breastcancer
patients – ultimately supporting improved outcomes.
Read more about the accuracy of MammaPrint and BluePrint in the NBRST study:
Our
#MammaPrint
and
#BluePrint
genomic tests are designed to match each patient to the right treatment. Read more findings like the below from the NBRST trial:
#breastcancer
During the NBRST trial,
#MammaPrint
&
#BluePrint
more accurately predicted patients’ responses to neo-adjuvant therapy – low-risk patients had a significantly lower response to neo-adjuvant chemotherapy (NAC) than high-risk patients. More on the findings:
Regardless of menopausal status,
#MammaPrint
and
#BluePrint
can provide more accurate predictions for patients with early-stage
#breastcancer
– leading to better planning. Learn more about findings from the NBRST study:
#research
By helping to minimize under- or over-treatment,
#MammaPrint
and
#BluePrint
can help doctors and their patients make more informed treatment decisions. Learn more about our genomic tests in the NBRST study:
#breastcancer
More than 1,000 patients were enrolled in the NBRST study, which followed participants for 5 years.
Click here to view findings from the trial, which demonstrate the accuracy of
#MammaPrint
and
#BluePrint
for
#breastcancer
treatment planning:
Calling all
#breastcancer
care teams! What are your patients most worried about? Vote today and we will
#DONATE
$10 to
@SusanGKomen
. Click here to vote now:
We had a great time at the
#PMWC22
conference! Thank you to everyone who stopped by our booth!
Click here to learn more about the latest data supporting the utility of
#MammaPrint
and
#BluePrint
for early-stage
#breastcancer
patients:
Calling all
#BreastCancer
care teams! CAST your vote today and we will
#DONATE
$10 to
@SusanGKomen
. With the overwhelming support we received during
#ASCO22
,
@Agendia
would like to open our poll to the public digitally! Click here to vote now: